Company Overview and News

0
Western Forest Products Inc. Announces Release Date of Second Quarter 2018 Results and Conference Call Details

2018-06-29 globenewswire
VANCOUVER, British Columbia, June 29, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) second quarter 2018 financial and operating results will be released on Thursday, August 2, 2018.
WFSTF WEF

0
Western Forest Products Inc. Announces Election of Directors

2018-05-03 globenewswire
VANCOUVER, British Columbia, May 03, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) announced today its voting results in respect of the election of all director nominees at its Annual and Special Meeting (the “Meeting”) held today as follows:
WFSTF WEF

0
Western Announces First Quarter 2018 Results

2018-05-03 globenewswire
VANCOUVER, British Columbia, May 02, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) reported adjusted EBITDA of $43.0 million in the first quarter of 2018, compared to adjusted EBITDA of $34.0 million in the first quarter of 2017, and $38.9 million reported in the fourth quarter of 2017. Operating income prior to restructuring and other income was $32.6 million in the first quarter of 2018, compared to $23.
WFSTF WEF

0
Western Forest Products Inc. Increases Dividend

2018-05-03 globenewswire
VANCOUVER, British Columbia, May 02, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) announced today that its Board of Directors has approved an increase of 12.5% in the quarterly dividend to $0.0225 per common share outstanding.
WFSTF WEF

0
Western Forest Products Inc. Announces Board of Director Changes

2018-04-11 globenewswire
VANCOUVER, British Columbia, April 11, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) announced today that Mr. Barrie Shineton will not be standing for re-election as a director at Western’s Annual and Special Meeting on May 3, 2018, and that Ms. Suzanne Blanchet has been proposed as a nominee for election to the Company’s Board of Directors (the “Board”).
WFSTF CADNF WEF

0
Western Forest Products Inc. Announces Release Date of First Quarter 2018 Results and Conference Call Details

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 29, 2018 (GLOBE NEWSWIRE) -- Western Forest Products Inc. (TSX:WEF) (“Western” or the “Company”) first quarter 2018 financial and operating results will be released on Wednesday, May 2, 2018.
WFSTF WEF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 958211203